- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Biodesix maintains $108M-$114M 2026 revenue outlook while planning ~120 sales reps | 2 | Seeking Alpha | ||
| Mi | Biodesix, Inc.: Biodesix Announces Second Quarter 2026 Results and Highlights | 37 | GlobeNewswire (Europe) | Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth... ► Artikel lesen | |
| Mi | BIODESIX INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| Mi | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | Biodesix, Inc.: Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 18.06. | Canaccord raises Biodesix stock price target to $27 on growth outlook | 4 | Investing.com | ||
| 23.05. | Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions | 1 | Insider Monkey | ||
| 20.05. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | Biodesix, Inc.: Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung Testing Strategy | 1 | GlobeNewswire (USA) | ||
| 07.05. | Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? | 1 | Zacks | ||
| 05.05. | Biodesix stock price target raised to $22 by Canaccord on revenue growth | 1 | Investing.com | ||
| 05.05. | Biodesix raises 2026 revenue outlook to $108M-$114M as it targets sustained adjusted EBITDA profitability | 1 | Seeking Alpha | ||
| 04.05. | Biodesix Q1 2026 Earnings Call: Complete Transcript | 4 | Benzinga.com | ||
| 04.05. | Earnings Call: Biodesix steigert Umsatz in Q1 2026 und hebt Prognose an | 1 | Investing.com Deutsch | ||
| 04.05. | Biodesix GAAP EPS of -$0.81 beats by $0.29, revenue of $25.6M beats by $2.42M | 1 | Seeking Alpha | ||
| 04.05. | Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| 04.05. | Biodesix, Inc.: Biodesix Announces First Quarter 2026 Results and Highlights | 193 | GlobeNewswire (Europe) | Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth... ► Artikel lesen | |
| 04.05. | BIODESIX INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 20.04. | Biodesix, Inc.: Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026 | 1 | GlobeNewswire (USA) | ||
| 09.04. | Biodesix, Inc.: Biodesix Recognized as a Top Workplace for Third Consecutive Year | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| VALNEVA | 2,291 | +0,04 % | Valneva streicht Jobs - warum die Aktie dennoch steigt | ||
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOFRONTERA | 2,490 | -2,73 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,490 | +1,22 % | Heidelberg Pharma: Was die Halbjahreszahlen über die Zukunft verraten | Bei Biotech-Unternehmen sagt eine einzelne Zahlenreihe selten alles, doch manchmal markiert sie einen Wendepunkt. Bei der Heidelberg Pharma AG (ISIN: DE000A11QVV0) könnte der Mitte Juli vorgelegte Halbjahresbericht... ► Artikel lesen | |
| NANOREPRO | 1,975 | -0,25 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.08.2026 / 07:15... ► Artikel lesen | |
| OCUGEN | 1,094 | -0,91 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,207 | +5,08 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,250 | -1,35 % | Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished | ||
| INFLARX | 1,585 | -0,69 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 45,180 | +0,30 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| GENMAB | 269,30 | +7,38 % | Genmab A/S Q2 Profit Declines | BRUSSELS (dpa-AFX) - Genmab A/S (GMAB) announced earnings for second quarter that Dropped, from last yearThe company's bottom line totaled $303 million, or $4.91 per share. This compares with... ► Artikel lesen | |
| EDITAS MEDICINE | 2,550 | +2,41 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,235 | +0,41 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen |
Das Unternehmen BIODESIX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 23,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.